

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Steffen GOLETZ, et al.) Group Art Unit: Not Yet Assigned
Application No.: U.S. National Phase of) Examiner: Not Yet Assigned
PCT/EP2004/009281)
Filed: Concurrently Herewith)
For: TUMOUR CELL LINES AND USES) Confirmation No.: Not Yet Assigned
THEREOF)

CERTIFICATE UNDER 37 CFR § 1.10 OF
MAILING BY "EXPRESS MAIL"

I hereby certify that this correspondence is being deposited
with the United States Postal Services "Express Mail Post
Office to Addressee" service under 37 CFR § 1.10 on
February 10, 2005 and is addressed to the Commissioner for
Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
Express Mail Label No. EV 755140911 US.


Heather Morgan

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed concurrently with the above-referenced application.

Copies of the listed documents are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

10/568098

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: February 10, 2006

By: 
Leslie A. McDonell
Reg. No. 34,872

IDS Form PTO/SB/08: Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	Not Yet Assigned	
			Filing Date	February 10, 2005	
			First Named Inventor	Steffen GOLETZ	
			Art Unit	Not Yet Assigned	
			Examiner Name	Not Yet Assigned	
			Attorney Docket Number	08358.0008-00000	
Sheet	1	of	1		

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials ¹	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			

Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 9740182 A	October 30, 1997	Pecher, Gabriele		
		WO 2004009632 A	January 29, 2004	Goltez, Steffen et al.		
		WO 2004018659 A	March 4, 2004	Glycotope GmBH		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		BÖHM et al., "Carbohydrate Recognition on MUC1-Expressing Targets Enhances Cytotoxicity of a T cell Subpopulation", <i>Scandinavian Journal of Immunology</i> , vol. 46, no. 1, pages 27-34, XP-002323076 (1997)	
		CAO et al., "Immunodetection of Epithelial Mucin (MUC1, MUC3) and Mucin-associated Glycotopes (TF, Tn, and sialosyl-Tn) in Benign and Malignant Lesions of Colonic Epithelium: Apolar Localization Corresponds to Malignant Transformation", <i>Virchows Archiv</i> , vol. 431, no. 3, pages 159-166, XP-002323077, (1997)	
		DUK et al., "Purification of Human Anti-TF (Thomsen-Friedenreich) and Anti-Tn Antibodies by Affinity Chromatography on Glycophorin A Derivatives and Characterization of the Antibodies by Microtiter Plate ELISA", <i>Archivum Immunologiae et Therapiae Experimentalis</i> , vol. 46, no. 2, pages 69-77, XP-008045186, (1998)	
		GOLLASCH et al., "Identification of Immunogenic Peptide-Mimics for the Thomsen-Friedenreich-Glycoantigen", <i>Annals of Hematology, Berlin, DE</i> , vol. 77, no. suppl. 2, page S84, XP-000960533, (1998)	Y
		ICHIYAMA, "Induction of Non-HLA-restricted Anti-tumour Effector Cells with Strong Cytotoxic Activity Using MUC1/B7 Cotransfected K562 Cells", <i>Cell Resource Center for Biomedical Research, Institute of Development, Aging, and Cancer, Tohoku University, Sendai, Japan</i> , vol. 51, no. 3-4, pages 93-11, XP-001182213, (2000)	
		KARSTEN et al., "Enhanced Binding of Antibodies to the DTR Motif of MUC1 Tandem Repeat Peptide is Mediated by Site-Specific Glycosylation", <i>Cancer Research, American Association for Cancer Research, Baltimore, MD, US</i> , vol. 58, no. 12, pages 2541-2549, XP-002112486, (June 15, 1998)	
		KUNZ, "Synthetic Glycopeptides for the Development of Tumour-selective Vaccines", <i>Journal of Peptide Science: an Official Publication of the European Peptide Society</i> , vol. 9, no. 9, pages 563-573, XP-00845163, (September 2003)	
Examiner Signature			Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**CERTIFICATE UNDER 37 CFR § 1.10 OF
MAILING BY "EXPRESS MAIL"**

I hereby certify that this correspondence is being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on February 10, 2005 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Express Mail Label No. EV 755140911 US.

Heather Morgan
Heather Morgan